![](/file.php/178092/McKenzie+13.png?thumbnail=1)
Feb 26, 2024
Paul shares his perspectives on his first year as CSL’s CEO, how CSL chooses its areas of focus, CSL’s strategy on sustainability and more.
![](/file.php/178070/Anthony+Farina+16X9.png?thumbnail=1)
Nov 30, 2023
CSL Chief Communications & Brand Officer talks to PRWeek about what work looks like these days – including the morning routine he sticks to even when working in other time zones.
![](/file.php/178071/Lutz+Bonacker+-+on+BIO+Europe+panel.jpg?thumbnail=1)
Nov 14, 2023
CSL Behring leaders are helping shape the conversation in Europe about how to give patients access to potentially game-changing treatments.
![](/file.php/178072/AMM+screenshot.png?thumbnail=1)
Nov 7, 2023
Three CSL leaders joined the Alliance for mRNA Medicines on a trip to the nation’s capital to discuss the future of mRNA technologies.
![](/file.php/178076/Meeting+on+the+Mesa+panel+photo.png?thumbnail=1)
Oct 16, 2023
CSL’s Debbie Drane recently spoke on a panel about how to keep momentum going following a record-setting year for cell and gene therapies.
![](/file.php/177957/McKenzie.jpg?thumbnail=1)
Apr 3, 2023
With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited.
![](/file.php/177894/Bill+Mezzanotte_1600x900.jpg?thumbnail=1)
Nov 3, 2022
CSL Head of R&D and Chief Medical Officer Bill Mezzanotte is interviewed in the Australian Financial Review (Subscription Required)
![](/file.php/177882/Joy+Linton_1600x900a.jpg?thumbnail=1)
Aug 19, 2022
CSL is taking action by setting 2030 carbon targets, CSL’s Chief Financial Officer says.